Menopausal Hormone Therapy

For twenty years one trial made hormone therapy after menopause look dangerous for everyone. Read properly, the same data say the risk depends on when you start, how the estrogen gets into you, and which progestogen comes with it: started within about ten years of menopause, as a patch or gel with body-identical progesterone, it is a well-supported treatment for hot flashes, sleep-wrecking night sweats and bone loss. It is not a heart-disease drug, a dementia drug or an anti-aging drug.

If menopause symptoms are affecting your life and you are under 60 or within ten years of your last period, hormone therapy is worth a serious conversation with a clinician. The modern default for a woman with a uterus is transdermal estradiol (patch, gel or spray) plus oral micronized progesterone, at the lowest dose that controls symptoms, reviewed every year with no fixed stop date. For vaginal dryness and painful sex, low-dose vaginal estrogen works on its own and carries very little systemic exposure.

Why the old scare was about the wrong women

The Women's Health Initiative, the big American trial whose 2002 results stopped a generation of prescribing, enrolled women with an average age of 63, typically more than ten years past menopause. It then generalised what happened to them to every woman. The idea that replaced it — the timing hypothesis — is that estrogen helps blood vessels that are still healthy and can temporarily destabilise ones already full of plaque [1].

The heart evidence for starting early is weaker than its reputation. The classic observational studies put coronary heart disease about 30–40% lower in users [2]. But a Swedish analysis of 919,614 women aged 50–58, designed to mimic a trial and strip out the fact that healthier women choose hormones, found oral estrogen-progestin linked to about 21% more ischaemic heart disease (an interval that just touches no effect), clearly more clots, and no excess with any skin preparation [3].

The two trials built to test timing directly measured artery scans, not heart attacks. ELITE showed the predicted timing effect on artery-wall thickening. KEEPS, in 727 women within three years of menopause, found no difference from placebo in artery thickening or coronary calcium [4]. Neither reduced heart attacks, strokes or deaths.

Pooling the randomised trials, hormone therapy had no effect on death from any cause overall; in the trials that started it early, deaths were about 30% lower [5]. That is a subgroup, not a headline. The trial's own 20-year review is the right summary: hormone therapy should not be used to prevent heart disease, stroke, dementia or other chronic disease at any age, even though its balance of benefit and risk is better in women under 60 treating symptoms [6].

Starting late is where the real harm sits: in women more than ten years past menopause or over 60, heart attack, stroke and clot risk rise in the first year or two, with no protective benefit to offset them [7].

In February 2026 the US Food and Drug Administration (FDA) removed the heart-disease, breast-cancer and dementia boxed warnings, keeping only the endometrial-cancer warning on systemic estrogen-alone products [8]. That changes the box, not the drug: no new trials lie behind it, and the Menopause Society's response was markedly more cautious.

Patch beats pill

How estrogen enters your body changes what it does. Pills pass through the liver first, which raises clotting factors, C-reactive protein (an inflammation marker) and triglycerides. Patches, gels and sprays skip the liver.

Oral estrogen carries a real signal for clots and ischaemic stroke; standard-dose transdermal estradiol does not raise either above baseline [9]. The condition is dose: higher doses raise stroke and clot risk whichever route you use [10].

The European Society of Endocrinology prefers transdermal whenever there is any cardiovascular risk factor — well-controlled diabetes or high blood pressure, obesity, high triglycerides, migraine with aura. A previous clot is different: it puts you outside the low-risk group and needs an individual risk assessment before any hormone therapy, not just a switch to a patch. The same guideline advises against testing for inherited clotting mutations such as factor V Leiden before starting [11].

Cancer: mostly a progestogen question

Women with a uterus need a progestogen alongside estrogen, because estrogen alone thickens the womb lining. That progestogen, not the estrogen, drives most of the breast cancer risk.

In the trials, estrogen alone did not raise breast cancer. In the Women's Health Initiative, women without a uterus taking estrogen alone had lower breast cancer incidence and mortality than on placebo [12].

The observational data disagree, and give the best absolute numbers. Pooling 108,647 breast cancers, the largest analysis found some excess with every type of systemic therapy, estrogen alone included (17% higher in the first four years of use, 33% in years 5–14). Five years of therapy from age 50 adds about one breast cancer per 50 users of estrogen with daily progestogen, one per 70 with intermittent progestogen, and one per 200 with estrogen alone, counted to age 69 [13]. Vaginal estrogen showed no excess.

The type of progestogen matters most. A 2026 review of 34 studies found combined therapy about 44% higher in breast cancer risk and estrogen alone not raised at all, though it could not separate individual progestogens [14]. The molecule-level evidence is older and observational. In a French cohort of 80,377 women, estrogen with micronized progesterone showed no increase, dydrogesterone a non-significant 16%, and other synthetic progestogens a clear 69% [15]. The neutrality has a time limit: after more than five years of current use, even progesterone or dydrogesterone carried about 31% higher risk [16]. Medroxyprogesterone acetate, the progestin behind the original trial's breast signal, and norethisterone are the ones to avoid where possible.

Ovary. Current or recent use raises ovarian cancer risk by about 40% even with under five years of use. Five years from about age 50 means roughly one extra ovarian cancer per 1,000 users and one extra death per 1,700; ten years, one per 600 and one death per 800. Risk falls after stopping but an excess was still visible ten years after long use [17].

Womb. Continuous daily progestogen brings the rate of endometrial hyperplasia (a precancerous thickening) back to roughly placebo levels, though the evidence is low-certainty. Sequential regimens, with progestogen for part of each month, do not: at one year they carried about 5.5 times the odds of hyperplasia. Trials have never had enough cancers to show protection against endometrial cancer itself [18]. Bowel cancer may be modestly lower, but the randomised evidence is mixed.

Bones: real protection, and a rebound when you stop

Hormone therapy is one of the most effective ways to prevent osteoporosis. In UK primary-care records covering 648,747 women with a first fracture, current use went with about 25% lower fracture odds [19]. Randomised trials agree: pooling 24 trials in 45,660 women, combined therapy cut clinical fractures by about 22% and estrogen alone by about 27% [20]. Roughly 70% of that trial data comes from older American women on oral conjugated estrogens, not the early transdermal regimen recommended here.

In the largest single trial, combined therapy prevented about 2.5 fractures per hundred women over 5.6 years, equally at every age, but across all outcomes there was no net benefit, even in women at high fracture risk, so hormone therapy is not a bone-only prescription [21]. An older pooled analysis of 22 small trials found a larger effect in women averaging under 60 [22], but for fractures the case for starting early rests on weak subgroups.

The part to plan for is stopping. In the one to ten years afterwards, fracture odds climb back to never-user levels, and slightly above them after combined therapy — about 14 extra fractures per 10,000 woman-years, concentrated in women who used it for under five years. Beyond ten years the odds fall below never-use again [23]. If you stop, taper slowly or bridge with another bone drug, and lift weights either way — see bone density.

Brain, mood and sleep

Started late, combined therapy raised dementia risk. In the Women's Health Initiative memory study, estrogen plus a synthetic progestin started at 65 or older doubled dementia risk — 40 cases against 21 on placebo [24]. Estrogen alone did not significantly raise it.

Started early, it neither harms nor helps. In KEEPS, four years of estrogen begun within three years of menopause left cognition no different from placebo ten years later [25]. Brain scans in 266 of those women showed no change in amyloid or brain structure [26]. The exception is menopause before 45, natural or surgical, where the long estrogen gap is itself a dementia risk and replacement is indicated [27].

One widely reported Danish registry study, of 5,589 dementia cases and 55,890 controls, linked estrogen-progestogen use to about 24% higher dementia rates, even in women who started at 55 or younger [28]. Women with early symptoms are more likely to be prescribed hormones, so it may be confounded, and the randomised scans point the other way. A signal to hold in mind, not to act on.

Mood is where hormone therapy helps quickly. The European Society of Endocrinology recognises perimenopause as an independent risk factor for depressive symptoms and hormone therapy as effective for them [29].

Sleep is thinner. In 342 women on hormone therapy, sleep-quality scores improved by about a quarter, but there was no comparison group and only 79 reached three years [30]. The likely mechanism is simply fewer night sweats waking you. See insomnia treatment, and rule out sleep-disordered breathing before blaming menopause.

How long to stay on it

Hormone therapy does not shorten life. A Danish registry of more than 800,000 women, over 104,000 of them users, found a slightly lower death rate in users (hazard ratio 0.96) [31] — but most were still in their fifties at the end of follow-up, too early for a lifetime verdict. The UK's NICE guideline also finds no rise in cardiovascular or overall mortality [32]. Over 18 years of trial follow-up, deaths from any cause did not move in either arm [33]. Healthy-user bias runs through all the observational figures, and a widely reported conference claim of about 60% lower odds of breast cancer, heart attack or stroke, from 120 million health records, has never been peer-reviewed.

There is no universal age to stop. Up to 40% of women in their 60s and about 15% in their 70s still have hot flashes, and in one small, unpublished clinic series of women over 65, 87% of those who tried stopping restarted because the flashes returned. The Menopause Society supports continuing past 65 with lower-dose transdermal regimens and active surveillance [34]. Starting after 65 is a different, riskier decision from continuing [35].

What to actually take

  • Estrogen: transdermal estradiol by default; oral estradiol is acceptable at low cardiometabolic risk. Conjugated equine estrogens are largely historical.
  • Progestogen, if you have a uterus: oral micronized progesterone 100–200 mg; dydrogesterone is an alternative where available [36].
  • Vaginal symptoms: low-dose vaginal estrogen or vaginal prasterone (DHEA) are the best-established treatments for dryness and painful sex; prasterone, in its placebo-controlled trial improved both over 12 weeks [37]. Absorption is minimal, so they suit many women who cannot take systemic hormones, including selected breast-cancer survivors with their oncologist's agreement.
  • Skip compounded "bioidentical" mixes. Licensed estradiol and micronized progesterone already are the body-identical hormones; compounded pellets and creams add dose variability and no guaranteed womb protection.

Before starting, expect a history (clots, stroke, heart disease, migraine with aura, liver disease, and personal or family cancers), blood pressure, a breast and pelvic exam, a lipid panel, HbA1c, liver, kidney and thyroid tests, and mammography by age, plus a pelvic ultrasound if you have abnormal bleeding. A DXA bone scan makes sense if you have bone-loss risk factors, repeated every 2–3 years. Recheck symptoms, blood pressure and weight at three months, then every 6–12 months, with an annual breast check and an annual decision on whether to continue.

If you can't or won't take hormones

Neurokinin blockers — fezolinetant and elinzanetant — calm the brain's temperature-control neurons. Both cut hot-flash frequency by about 60–65% over 12 weeks, but placebo fell 37–43%, leaving roughly 25 percentage points to the drug [38], [39]. Fezolinetant carries a US boxed warning for rare serious liver injury and needs liver tests before starting and five more in the first nine months [40]; elinzanetant has no boxed warning but needs liver tests before starting and at three months. Neither should be started if liver values are already twice the upper limit of normal.

Antidepressants such as paroxetine and venlafaxine cut hot flashes by 40–60% on paper [41], but across six paroxetine trials in 1,486 women, 79% of the improvement was matched on placebo [42]. The mood benefit is separate and real.

Mind-body practices — yoga, mindfulness, qigong, music, dance — produced large improvements in sleep, depression and anxiety across trials in over 1,500 women, though the trials were small and short [43].

Soy isoflavones cut hot flushes only modestly in trials, and menopause specialists do not recommend soy foods or extracts for them; see Soy.

Estetrol is not an alternative to hormones but a newer oral estrogen, approved in the EU in March 2026 but not approved for menopause in the US; women with a uterus still need a separate progestogen with it. In a 12-week trial of 640 women it reduced hot flashes, but drug-related side effects hit about half to nearly 60% of users against a fifth on placebo [44]. Hopes that it is gentler on clotting are unproven: there are no long-term clot or heart-outcome data yet.

What it doesn't do

  • It isn't a heart or metabolism drug. Guidelines say it slows visceral-fat gain and improves blood sugar when started early, but no trial effect size backs that here, and cardiovascular prevention is not on its own a reason to prescribe it.
  • It isn't proven for muscle. Muscle falls about 0.6% a year after menopause [45], but a review of 32 studies called the evidence that estrogen preserves it "largely conflicting and inconclusive" [46]. Inactive postmenopausal women had nearly four times the odds of slow walking speed [47]. In older adults with muscle loss, exercise combined with nutrition support is what has measured benefits [48] — see resistance training and protein.
  • It isn't a proven anti-aging clock-slower. Menopause does speed up DNA-methylation aging [49], but trial evidence that hormone therapy slows it is preliminary.
  • It doesn't fix all skin aging. Across 15 trials, collagen and skin thickness improved a lot, elasticity only slightly, and dryness not at all [50].
  • It isn't your dementia strategy. Blood pressure, exercise, sleep and treating hearing loss (an association, not yet proven causal) matter more — see dementia prevention.

Who should be careful

Don't take systemic hormone therapy with: a history of hormone-receptor-positive breast cancer, an active estrogen-dependent cancer, an active blood clot, unexplained vaginal bleeding, severe uncontrolled heart disease, or severe active liver disease.

Discuss carefully first if you have: a previous clot (individual assessment, not just a route switch); any cardiovascular risk factor (use transdermal); more than ten years since menopause or an age over 60–65 at starting; a past ovarian cancer (serous and granulosa-cell tumours are hormone-dependent, so non-hormonal options come first) [51]; or a uterus and a plan to take estrogen without a continuous progestogen. Revisit the decision every year, because breast and ovarian risk grow with duration. The biggest absolute benefits probably go to women whose symptoms or health have started to slide; for a symptom-free, healthy 50-year-old the longevity case is modest.

Further reading

  • Manson JE et al. The Women's Health Initiative Randomized Trials and Clinical Practice: A Review. JAMA 2024.[52]
  • Mehta JM, Chester RC, Kling JM. The Timing Hypothesis: Hormone Therapy for Treating Symptomatic Women During Menopause and Its Relationship to Cardiovascular Disease. J Womens Health 2019.[53]
  • Lumsden MA, et al. European society of endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause. Eur J Endocrinol 2025.[54]
  • Kim Y, et al. The 2025 Menopausal Hormone Therapy Guidelines - Korean Society of Menopause. J Menopausal Med 2025.[55]
  • Benkhadra K et al. Menopausal Hormone Therapy and Mortality: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2015.[56]
  • Mikkelsen AP, et al. Menopausal hormone therapy and long term mortality: nationwide, register based cohort study. BMJ 2026.[57]
  • Fournier A et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008.[58]
  • Vinogradova Y et al. Discontinuation of menopausal hormone therapy and risk of fracture: nested case-control studies using routinely collected primary care data. Lancet Healthy Longev 2025.[59]
  • Gleason CE, et al. Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study. PLoS Med 2024.[60]
  • Labrie F et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness. Menopause 2016.[61]
  • Menopause: identification and management. NICE guideline NG23, 2024 update.[62]
  • Ongoing individualized hormone therapy appears to have no age limit. The Menopause Society press release, 2024.[63]

— § —